Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Melanoma: HELP
Articles by Mauro Alaibac
Based on 18 articles published since 2008
||||

Between 2008 and 2019, M. Alaibac wrote the following 18 articles about Melanoma.
 
+ Citations + Abstracts
1 Review Melanoma: epidemiology, risk factors, pathogenesis, diagnosis and classification. 2014

Rastrelli, Marco / Tropea, Saveria / Rossi, Carlo Riccardo / Alaibac, Mauro. ·Melanoma and Sarcoma Unit, Veneto Institute of Oncology, IOV-IRCCS, Padova, Italy marco.rastrelli@ioveneto.it. · Melanoma and Sarcoma Unit, Veneto Institute of Oncology, IOV-IRCCS, Padova, Italy. · Melanoma and Sarcoma Unit, Veneto Institute of Oncology, IOV-IRCCS and Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy. · Dermatology Unit, University of Padova, Padova, Italy. ·In Vivo · Pubmed #25398793.

ABSTRACT: This article reviews epidemiology, risk factors, pathogenesis and diagnosis of melanoma. Data on melanoma from the majority of countries show a rapid increase of the incidence of this cancer, with a slowing of the rate of incidence in the period 1990-2000. Males are approximately 1.5-times more likely to develop melanoma than females, while according to other studies, the different prevalence in both sexes must be analyzed in relation with age: the incidence rate of melanoma is grater in women than men until they reach the age of 40 years, however, by 75 years of age, the incidence is almost 3-times as high in men versus women. The most important and potentially modifiable environmental risk factor for developing malignant melanoma is the exposure to ultraviolet (UV) rays because of their genotoxic effect. Artificial UV exposure may play a role in the development of melanoma. The most important host risk factors are the number of melanocytic nevi, familiar history and genetic susceptibility. A patient with a personal history of melanoma must be considered at greater risk for subsequent melanoma. Indeed approximately 1-8% of patients with prior history of melanoma will develop multiple primary melanomas. We herein review the dermatological diagnosis and classification of melanoma.

2 Review Cutaneous melanoma in solid organ transplant patients. 2014

Russo, I / Piaserico, S / Belloni-Fortina, A / Alaibac, M. ·Dermatology Unit, Department of Medicine University of Padua, Padua, Italy - mauro.alaibac@unipd.it. ·G Ital Dermatol Venereol · Pubmed #25068225.

ABSTRACT: Solid organ transplant patients are at greatly increased risk of developing a wide variety of skin cancers, particularly epithelial skin cancers. On the other hand, it is well known that an intact immune system limits the development of benign melanocytic lesions. The eruptive nevi phenomenon, which we can observe in solid organ transplant recipients, is indicative of the relationship between melanocyte proliferation and immune system. Regression of melanocytic nevi after restoration of complete immune responsiveness is a further clinical example the role of immunosurveillance on melanocyte proliferation. However, melanoma incidence in organ transplant recipients appears only 2-3 folds higher than in general population. To this regard, organ transplant recipients who develop de novo melanomas thicker than 2mm seem to have a significantly worse outcome with a greatly increased risk of dying of metastatic melanoma, whereas those who develop a ≤2 mm thickness melanoma seem to have a prognosis similar to that of the general population. Furthermore, there is no evidence supporting an increased risk of melanoma recurrences after transplant in patients with a history of low-risk melanoma. Melanoma is also one of the most frequent and lethal donor-derived malignancies suggesting that a history of invasive melanoma should be considered an absolute contraindication to donation. The aim of this review is to investigate the relationship between immunosuppression and melanoma and to discuss its clinical implications for the management of transplant-associated melanoma.

3 Review Melanoma m1: diagnosis and therapy. 2014

Rastrelli, Marco / Tropea, Saveria / Pigozzo, Jacopo / Bezzon, Elisabetta / Campana, Luca Giovanni / Stramare, Roberto / Alaibac, Mauro / Rossi, Carlo Riccardo. ·Melanoma and Sarcoma Unit, Veneto Institute of Oncology IOV-IRCCS Padova, Italy. marco.rastrelli@ioveneto.it. ·In Vivo · Pubmed #24815827.

ABSTRACT: This article reviews the epidemiology, pathogenesis, diagnosis, prognostic factors and treatment of metastatic melanoma, including the most recent developments in the specific field. It examines the sequential and non-linear models of development and progression of melanoma and the main molecular disorder involved in these processes. Clinical and diagnostic aspects have been divided according to clinical staging. Surgical resectability, the site and number of metastases, the number of involved organs, the duration of remission, serum lactate dehydrogenase levels and tumor doubling-time have the greatest prognostic value. Surgical treatment has been analyzed considering its rational function and examining all sites involved in metastasis. We also discuss the palliative role of radiotherapy in relation to various metastatic sites, chemotherapy and recently introduced targeted-therapy. The association of newer drugs and new biological therapies such as ipilimumab and verumafenib have improved the treatment landscape of stage IV melanoma.

4 Review Meyerson's phenomenon in a patient affected by high-risk melanoma under treatment with interferon-α. 2012

Zonta, Elisa / Chiarion, Vanna / Zarian, Haik / Peserico, Andrea / Alaibac, Mauro. · ·Melanoma Res · Pubmed #22543678.

ABSTRACT: -- No abstract --

5 Review Immunosuppression and melanocyte proliferation. 2009

Zattra, Edoardo / Fortina, Anna Belloni / Bordignon, Matteo / Piaserico, Stefano / Alaibac, Mauro. ·University of Padua, Padova, Italy. ·Melanoma Res · Pubmed #19194340.

ABSTRACT: Melanocytes are pigmented cells derived from the neural crest; their proliferation is restrained by immune system. The eruption of nevi after an immunosuppressive condition is a peculiar phenomenon indicating that the immune system may play a major role in limiting proliferation of melanocytes. In this review, we analyze the role of immunosuppressive regimens on melanocyte proliferation. In particular, we discuss the eruptive nevi phenomenon, which is determined by the inability of the immune system to inhibit melanocyte proliferation. These clinical observations indicate that the immune system has a pivotal role in restraining melanocyte proliferation. However, although the role of the immune system in the development of nonmelanoma skin cancer has been shown clearly in several studies involving organ transplant patients, the role of immunosuppression in melanoma genesis has not yet been established. Further investigations are required to establish the real immunogenicity of melanoma, particularly in the light of the dichotomy between the eruptive nevi phenomenon in immunosuppressed patients and the low incidence of melanoma in transplanted patients.

6 Article Clinicopathological predictors of recurrence in nodular and superficial spreading cutaneous melanoma: a multivariate analysis of 214 cases. 2017

Pizzichetta, Maria A / Massi, Daniela / Mandalà, Mario / Queirolo, Paola / Stanganelli, Ignazio / De Giorgi, Vincenzo / Ghigliotti, Giovanni / Cavicchini, Stefano / Quaglino, Pietro / Corradin, Maria T / Rubegni, Pietro / Alaibac, Mauro / Astorino, Stefano / Ayala, Fabrizio / Magi, Serena / Mazzoni, Laura / Manganoni, Maria Ausilia / Talamini, Renato / Serraino, Diego / Palmieri, Giuseppe / Anonymous1471021. ·Division of Oncology B, CRO Aviano National Cancer Institute, Via Franco Gallini 2, 33081, Aviano, Italy. pizzichetta@cro.it. · Division of Pathological Anatomy, Department of Surgery and Translational Medicine, University of Florence, Florence, Italy. · Unit of Medical Oncology, Papa Giovanni XXIII Hospital, Bergamo, Italy. · Department of Medical Oncology, National Institute for Cancer Research, IRCCS San Martino, Genoa, Italy. · Skin Cancer Unit, Istituto Tumori Romagna (IRST), Meldola, Italy. · Department of Dermatology, University of Parma, Parma, Italy. · Department of Dermatology, University of Florence, Florence, Italy. · Clinic of Dermatology, IRCCS San Martino-IST, Genoa, Italy. · Department of Dermatology, Fondazione Ospedale Maggiore Policlinico IRCCS, Milan, Italy. · Dermatologic Clinic, Dept Medical Sciences, University of Torino, Turin, Italy. · Division of Dermatology, Pordenone Hospital, Pordenone, Italy. · Department of Dermatology, University of Siena, Siena, Italy. · Department of Dermatology, University of Padova, Padua, Italy. · Division of Dermatology, Celio Hospital, Rome, Italy. · National Cancer Institute, "Fondazione G. Pascale"-IRCCS, Naples, Italy. · Department of Dermatology, ASST degli Spedali Civili di Brescia, Brescia, Italy. · Unit of Epidemiology and Biostatistics, CRO Aviano National Cancer Institute, Aviano, Italy. · Unit of Cancer Genetics, Institute of Biomolecular Chemistry (ICB), National Research Council (CNR), Sassari, Italy. ·J Transl Med · Pubmed #29115977.

ABSTRACT: BACKGROUND: Nodular melanoma (NM) accounts for most thick melanomas and because of their frequent association with ulceration, fast growth rate and high mitotic rate, contribute substantially to melanoma-related mortality. In a multicentric series of 214 primary melanomas including 96 NM and 118 superficial spreading melanoma (SSM), histopathological features were examined with the aim to identify clinicopathological predictors of recurrence. METHODS: All consecutive cases of histopathologically diagnosed primary invasive SSM and NM during the period 2005-2010, were retrieved from the 12 participating Italian Melanoma Intergroup (IMI) centers. Each center provided clinico-pathological data such as gender, age at diagnosis, anatomical site, histopathological conventional parameters, date of excision and first melanoma recurrence. RESULTS: Results showed that NM subtype was significantly associated with Breslow thickness (BT) at multivariate analysis: [BT 1.01-2 mm (OR 7.22; 95% CI 2.73-19.05), BT 2.01-4 mm (OR 7.04; 95% CI 2.54-19.56), and BT > 4 mm (OR 51.78; 95% CI 5.65-474.86) (p < 0.0001)]. Furthermore, mitotic rate (MR) was significantly correlated with NM histotype: [(MR 3-5 mitoses/mm CONCLUSIONS: We found that NM subtype was significantly associated with higher BT and MR but it was not a prognostic factor since it did not significantly correlate with melanoma recurrence rate. Conversely, increased BT and MR as well as SNLB positivity were significantly associated with a higher risk of melanoma recurrence.

7 Article A comparative study of the cutaneous side effects between BRAF monotherapy and BRAF/MEK inhibitor combination therapy in patients with advanced melanoma: a single-centre experience. 2017

Russo, Irene / Zorzetto, Ludovica / Frigo, Anna Chiara / Chiarion Sileni, Vanna / Alaibac, Mauro. ·Unit of Dermatology, University of Padua, Via Gallucci 4, 35128 Padova, Italy. · Unit of Biostatistics, Epidemiology and Public Health, Department of Cardiac, Thoracic and Vascular Sciences University of Padua Via Loredan, 18, 35131 Padova, Italy. · Unit of Medical Oncology, Veneto Institute of Oncology IOV-IRCCS, 35128 Padova, Italy. ·Eur J Dermatol · Pubmed #29084636.

ABSTRACT: Patients with advanced melanoma have a poor prognosis. Since the discovery of BRAF mutations in cutaneous melanoma, new pharmacological agents have been developed to inhibit this target. Although the survival of patients with advanced melanoma has improved with BRAF inhibitors, the emergence of drug resistance and the high incidence of cutaneous side effects represent important limitations. The aim of our study was to compare the incidence of cutaneous side effects between BRAF inhibitor monotherapy and BRAF and MEK inhibitor combination therapy in our cohort of patients. This study was a longitudinal prospective observational study. The study population comprised 83 patients with advanced cutaneous melanoma presenting with BRAF V600 mutation. The inclusion criteria included: age above 18 years, metastatic cutaneous melanoma or melanoma with high risk of metastasis, the presence of BRAF V600 mutation, and treatment with BRAF inhibitors or a combination of BRAF and MEK inhibitors. The majority of patients developed skin toxicity during treatment. The most common cutaneous side effects were localized hyperkeratosis and verrucous keratosis. Other cutaneous side effects observed were photosensitivity, squamous cell carcinoma, and keratoacanthoma. Our results indicate that cutaneous side effects are generally observed during BRAF inhibitor monotherapy and are significantly different from those observed in patients treated with combination therapy.

8 Article Long-term Survival of Patients With Invasive Ultra-thin Cutaneous Melanoma: A Single-center Retrospective Analysis. 2016

Vecchiato, Antonella / Zonta, Elisa / Campana, Luca / Dal Bello, Giacomo / Rastrelli, Marco / Rossi, Carlo Riccardo / Alaibac, Mauro. ·From the Melanoma and Soft Tissue Sarcoma Unit, Veneto Institute of Oncology, IOV-IRCCS, Padua, Italy (AV, LC, MR, CRR) · and Dermatology Unit, University of Padua, Padua, Italy (EZ, GDB, MA). ·Medicine (Baltimore) · Pubmed #26765437.

ABSTRACT: The incidence of cutaneous melanoma is increasing worldwide, especially for thin melanoma (Breslow ≤1 mm). Thin cutaneous melanoma has a favorable prognosis but there are few data about the prognosis of patients with ultra-thin cutaneous melanoma (Breslow ≤ 0.5 mm). Our aim was to investigate the disease-free survival among patients with invasive cutaneous melanoma with Breslow ≤ 0.5 mm after 10 years from the initial diagnosis.A retrospective review of 240 cutaneous melanoma patients with Breslow ≤ 0.5 mm was performed. Recurrence, death from cutaneous melanoma, and disease-free survival were all identified.In the whole group of patients, we observed only 2 deaths from cutaneous melanoma. Median follow-up was 13, 11 years. Among all 240 patients, 221 were alive and disease free, 2 died of cutaneous melanoma, 11 died of other non-neoplastic diseases, 5 died of other neoplastic diseases different from melanoma, and 1 patient had a local recurrence; therefore the 10-year melanoma survival rate was 99.6%.Our data indicate that death from cutaneous melanoma in the group of patients with Breslow ≤0.5 mm was a very rare event and that diagnosis at this stage dramatically decreases the risk of developing metastatic tumors to a <0.5% also after a 10-year period of follow-up. Limitation of the study includes the fact that other risk factors for melanoma, notably ulceration, and mitotic rate, were not evaluated.

9 Article Differences in clinicopathological features and distribution of risk factors in Italian melanoma patients. 2015

Fava, P / Astrua, C / Chiarugi, A / Crocetti, E / Pimpinelli, N / Fargnoli, M C / Maurichi, A / Rubegni, P / Manganoni, A M / Bottoni, U / Catricalà, C / Cavicchini, S / Santinami, M / Alaibac, M / Annetta, A / Borghi, A / Calzavara Pinton, P / Capizzi, R / Clerico, R / Colombo, E / Corradin, M T / De Simone, P / Fantini, F / Ferreli, C / Filosa, G / Girgenti, V / Giulioni, E / Guarneri, C / Lamberti, A / Lisi, P / Nardini, P / Papini, M / Peris, K / Pizzichetta, M A / Salvini, C / Savoia, P / Strippoli, D / Tolomio, E / Tomassini, M A / Vena, G A / Zichichi, L / Patrizi, A / Argenziano, G / Simonacci, M / Quaglino, P. ·Dermatologic Clinic, Department of Medical Sciences, University of Turin, Turin, Italy. ·Dermatology · Pubmed #25659983.

ABSTRACT: BACKGROUND: No studies are available in the literature on the distribution of different melanoma features and risk factors in the Italian geographical areas. OBJECTIVE: To identify the differences in clinical-pathological features of melanoma, the distribution of risk factors and sun exposure in various Italian macro-areas. METHODS: Multicentric-observational study involving 1,472 melanoma cases (713 north, 345 centre, 414 south) from 26 referral centres belonging to the Italian Multidisciplinary Group for Melanoma. RESULTS: Melanoma patients in northern regions are younger, with thinner melanoma, multiple primaries, lower-intermediate phototype and higher counts of naevi with respect to southern patients; detection of a primary was mostly connected with a physician examination, while relatives were more involved in the south. Northern patients reported a more frequent use of sunbeds and occurrence of sunburns before melanoma despite sunscreen use and a lower sun exposure during the central hours of the day. CONCLUSIONS: The understanding of differences in risk factors distribution could represent the basis for tailored prevention programmes.

10 Article Histopathological characteristics of subsequent melanomas in patients with multiple primary melanomas. 2014

Vecchiato, A / Pasquali, S / Menin, C / Montesco, M C / Alaibac, M / Mocellin, S / Campana, L G / Nitti, D / Rossi, C R. ·Melanoma and Sarcomas Unit, Veneto Institute of Oncology, Padova, ItalyDepartment of Oncological and Surgical Sciences, University of Padova, Padova, ItalyImmunology and Molecular Oncology Unit, Veneto Institute of Oncology, Padova, ItalyPathology Unit, Veneto Institute of Oncology, Padova, ItalyDermatology Unit, University of Padova, Padova. ·J Eur Acad Dermatol Venereol · Pubmed #23216522.

ABSTRACT: BACKGROUND: Multiple primary melanomas (MPM) occur in up to 20% of melanoma patients, and subsequent tumours seem to have a favourable histopathological pattern. OBJECTIVE: A prospectively collected cohort of 194 patients with MPM was retrospectively reviewed to investigate clinical and histopathological features of first and subsequent melanomas. METHODS: Patients with MPM who were diagnosed at our Department (1985-2011) and who attended at least a follow-up control yearly were identified. RESULTS: The number of nevi was <10, 10-50 and >50 in 8.7%, 41% and 50.3% of patients respectively. Histopathological dysplastic nevi have been diagnosed in 105 patients. During a median follow-up of 58 months, 159 (81.9%), 24 (12.3%), 7 (3.6%) and 4 (2%) patients developed 2, 3, 4 and ≥ 5 melanomas, respectively. The median time to second primary melanoma was 45 months. The second primary melanoma was diagnosed within 1-year and after 5-year from the first melanoma in 36.6% and 17.3% of patients respectively. First and second primary melanomas were in situ in 41 (21%) and 104 (54%) patients respectively (P < 0.001). Among patients with ≥ 2 invasive melanomas (N = 80), median tumour thickness and ulceration of first and second primaries were 0.91 and 0.44 mm (P <0.001), and 32% and 7.7% (P = 0.001) respectively. CONCLUSIONS: Subsequent melanomas occurred within 1-year from the appearance of the first melanoma in 36% of patients with MPM, while a late melanoma diagnosis was detected in 17% of cases. Second primary melanoma had favourable histopathological features. Our findings support long-term skin surveillance to detect subsequent melanomas at an early stage.

11 Article Achromic superficial spreading melanoma accidentally treated with imiquimod. 2012

Zattra, Edoardo / Salmaso, Roberto / Tonin, Elena / Alaibac, Mauro. ·Dermatology Unit, University of Padua, Padova, Italy. ·Acta Derm Venereol · Pubmed #21725584.

ABSTRACT: -- No abstract --

12 Article Nevus spilus and melanoma: case report and review of the literature. 2010

Corradin, Maria Teresa / Zattra, Edoardo / Fiorentino, Renzo / Alaibac, Mauro / Belloni-Fortina, Anna. ·Unit of Dermatology, Azienda Ospedaliera Santa Maria degli Angeli di Pordenone, Padua, Italy. ·J Cutan Med Surg · Pubmed #20338124.

ABSTRACT: BACKGROUND: Nevus spilus is characterized by a pigmented patch with scattered flat or maculopapular speckles. Nevus spilus was first described by Burkley in 1842. Since then, this lesion has been widely debated in the literature, particularly for the possible occurrence of melanoma within the lesion. OBJECTIVE: We describe the case of a 65-year-old female presenting with a nodular achromic melanoma that occurred within a nevus spilus on the left thigh. CONCLUSION: Our observation is consistent with the idea that this entity in some circumstances may have the ability to evolve into a malignant melanoma.

13 Article Functional impairment of p16(INK4A) due to CDKN2A p.Gly23Asp missense mutation. 2009

Scaini, Maria Chiara / Rossi, Elisabetta / de Siqueira Torres, Paula Lobao Antunes / Zullato, Daniela / Callegaro, Monia / Casella, Cinzia / Quaggio, Monica / Agata, Simona / Malacrida, Sandro / Chiarion-Sileni, Vanna / Vecchiato, Antonella / Alaibac, Mauro / Montagna, Marco / Mann, Graham J / Menin, Chiara / D'Andrea, Emma. ·Section of Oncology, Department of Oncology and Surgical Sciences, University of Padova, via Gattamelata, 64, I-35128 Padova, Italy. mariachiara.scaini@unipd.it ·Mutat Res · Pubmed #19712690.

ABSTRACT: The CDKN2A locus encodes for two distinct tumor suppressor proteins, p16(INK4A) and p14(ARF), involved in cell cycle regulation. CDKN2A germline mutations have been associated with familial predisposition to melanoma and other tumor types. Besides bona-fide pathogenic mutations, many sequence variants have been identified, but their effect is not well known. We detected the p.Gly23Asp missense mutation in one of the two tested melanoma patients of a family with three melanoma cases. Even though the mutated amino acid is located in a conserved domain that specifically binds to and blocks the function of CDK4/6, its lack of segregation with disease suggested a series of functional assays to discriminate between a pathogenic variant and a neutral polymorphism. The effect of this mutation has been investigated exploiting four p16(INK4A) properties: its ability (i) to bind CDK4, (ii) to inhibit pRb phosphorylation, (iii) to evenly localize in the cell, and (iv) to cause cell cycle arrest. The mutant protein properties were evaluated transfecting three different cell lines (U2-OS and NM-39, both p16-null, and SaOS 2, p53 and pRb-null) with plasmids expressing either p16(wt), p16(23Asp), or the p16(32Pro) pathogenic variant. We found that p16(23Asp) was less efficient than p16(wt) in CDK4 binding, in inhibiting pRb phosphorylation, in inducing G1 cell cycle arrest; moreover, its pattern of distribution throughout the cell was suggestive of protein aggregation, thus assessing a pathogenic role for p16(23Asp) in familial melanoma.

14 Article Role of the EGF +61A>G polymorphism in melanoma pathogenesis: an experience on a large series of Italian cases and controls. 2009

Casula, Milena / Alaibac, Mauro / Pizzichetta, Maria A / Bono, Riccardo / Ascierto, Paolo A / Stanganelli, Ignazio / Canzanella, Sergio / Palomba, Grazia / Zattra, Edoardo / Anonymous3140634 / Palmieri, Giuseppe. ·Unit of Cancer Genetics, Institute of Biomolecular Chemistry, Consiglio Nazionale delle Ricerche, Sassari, Italy. casulam@yahoo.it ·BMC Dermatol · Pubmed #19624835.

ABSTRACT: BACKGROUND: A single nucleotide polymorphism (61A>G) in the epidermal growth factor (EGF) gene has been implicated in both melanoma pathogenesis and increased melanoma risk. To further evaluate this association, we conducted a case-control study in a clinic-based Italian population. METHODS: Individuals with less than 10 (N = 127) or more than 100 (N = 128) benign nevi, and patients with cutaneous melanoma (N = 418) were investigated for the EGF +61A>G polymorphism, using an automated sequencing approach. RESULTS: Overall, no difference in EGF genotype frequencies was observed among subjects with different number of nevi as well as when non-melanoma healthy controls were compared with the melanoma patients. However, a heterogeneous distribution of the frequencies of the G/G genotype was detected among cases and controls originating from North Italy (21.1 and 18.3%, respectively) vs. those from South Italy (12.6 and 17.1%, respectively). CONCLUSION: Our findings further suggest that EGF +61A>G polymorphism may have a limited impact on predisposition and/or pathogenesis of melanoma and its prevalence may vary in different populations.

15 Minor Dermoscopic diagnosis of amelanotic/hypomelanotic melanoma. 2017

Pizzichetta, M A / Kittler, H / Stanganelli, I / Ghigliotti, G / Corradin, M T / Rubegni, P / Cavicchini, S / De Giorgi, V / Bono, R / Alaibac, M / Astorino, S / Ayala, F / Quaglino, P / Pellacani, G / Argenziano, G / Guardoli, D / Specchio, F / Serraino, D / Talamini, R / Anonymous24890882. ·Division of Medical Oncology - Preventive Oncology, Centro di Riferimento Oncologico, National Cancer Institute, Aviano, Italy. · Department of Dermatology, Medical University of Vienna, Vienna, Austria. · Skin Cancer Unit, Istituto Tumori Romagna (IRST), Meldola, Department of Dermatology, University of Parma, Italy. · IRCCS San Martino - 1st Clinic of Dermatology, Genova, Italy. · Division of Dermatology, Pordenone Hospital, Pordenone, Italy. · Department of Dermatology, University of Siena, Siena, Italy. · Department of Dermatology, Fondazione Ospedale Maggiore Policlinico IRCCS, Milan, Italy. · Department of Dermatology, University of Florence, Florence, Italy. · Istituto Dermopatico Immacolata, IRCCS, Rome, Italy. · Department of Dermatology, University of Padova, Italy. · Division of Dermatology, Celio Hospital, Rome, Italy. · National Cancer Institute, 'Fondazione G. Pascale'-IRCCS, Naples, Italy. · Dermatologic Clinic, Department of Medical Sciences, University of Torino, Torino, Italy. · Department of Dermatology, University of Modena and Reggio Emilia, Modena, Italy. · Dermatology Unit, Second University of Naples, Naples, Italy. · Skin Cancer Unit, Arcispedale Santa Maria Nuova IRCCS, Reggio Emilia, Italy. · Unit of Epidemiology and Biostatistics, Centro di Riferimento Oncologico, National Cancer Institute, Aviano, Italy. ·Br J Dermatol · Pubmed #27681347.

ABSTRACT: -- No abstract --

16 Minor Contribution of susceptibility gene variants to melanoma risk in families from the Veneto region of Italy. 2011

Menin, Chiara / Vecchiato, Antonella / Scaini, Maria Chiara / Elefanti, Lisa / Funari, Gloria / De Salvo, Gian Luca / Quaggio, Monica / Tognazzo, Silvia / Agata, Simona / Dalla Santa, Silvia / Montagna, Marco / Alaibac, Mauro / Chiarion-Sileni, Vanna / D'Andrea, Emma. · ·Pigment Cell Melanoma Res · Pubmed #21672182.

ABSTRACT: -- No abstract --

17 Minor Melanoma in skin affected with keratoderma palmoplantaris hereditaria (Mal de Meleda): Treatment with excision and grafting. 2009

Sartore, Leonardo / Bordignon, Matteo / Bassetto, Franco / Voltan, Anna / Tomat, Valeria / Alaibac, Mauro. · ·J Am Acad Dermatol · Pubmed #19539863.

ABSTRACT: -- No abstract --

18 Minor Melanoma and immunosuppression. 2009

Belloni-Fortina, Anna / Piaserico, Stefano / Tonin, Elena / Alaibac, Mauro. · ·Dermatology · Pubmed #18832814.

ABSTRACT: -- No abstract --